

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Rebecca Cunningham', written in a cursive style.

Rebecca Cunningham
Vice President for Research

March 2023

Attachment A

Project #1

Research Agreement between the University and Eli Lilly and Company Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Mechanisms Mediating the Hindbrain Control of Energy Balance - CNTF and Identifying CNS Circuits that Determine the Body Weight Set Point 23-PAF02145 it Parent	U-M Project ID: 23-PAF04696
Direct Sponsor: Eli Lilly and Company	
Principal Investigator/Department: Randy Seeley, Surgery	
Project Duration: Four (4) Years	Funding Support: \$2,104,226
Purpose: The purpose of this project is to define and distinguish mechanisms mediating the hindbrain control of energy balance within the body with the ultimate objective of potentially being able to develop weight loss therapies distinct from the pharmacological tools currently available.	
<u>University Employee; University Title; Relationship with Eli Lilly and Company</u>	
<ul style="list-style-type: none">• Marschall Runge; Executive Vice President for Medical Affairs and Dean of the Medical School; Board of Directors Member	

Project #2

Subcontract Agreement between the University and NX Fuels, Inc. (dba Carbon Fuels, Inc.) Reviewed by the UMOR Conflict of Interest Review Committee	
<u>Project Information</u>	
Title: Highly Efficient and Robust Photocatalyst for CO2 Conversion to Valuable Fuels Using Renewable Solar	U-M Project ID: 23-PAF02214
Direct Sponsor: NX Fuels, Inc.	Prime Sponsor: National Science Foundation
Principal Investigator/Department: Zetian Mi, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS – ECE) Division	
Project Duration: Two (2) Years	Funding Support: \$450,000
Purpose: The purpose of this project is to design, grow/deposit, and characterize III-nitride photocatalyst materials and to significantly advance the artificial photosynthesis conversion of CO2 to methanol.	
<u>University Employee; University Title; Relationship with NX Fuels, Inc.</u>	
<ul style="list-style-type: none">• Zetian Mi; Professor, EECS-ECE Division; Partial Owner	

Project #3

**Third Amendment to Other Sponsored Activity Agreement between the University and Rappta Therapeutics Oy
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: Testing of small molecule PP2A activators in cellular and in vivo systems

U-M Project ID: 22-PAF07236
under AWD016016

Direct Sponsor: Rappta Therapeutics Oy

Principal Investigator/Department: Goutham Narla, Internal Medicine - Genetic Medicine

Agreement Originally Approved by the Regents: May 21, 2020

First Amendment Approved by the Regents: December 9, 2021

Second Amendment Approved by the Regents: July 21, 2022

Current Project Duration: Thirty-One (31) Months

Current Funding Support: \$2,300,000
Additional Funding Support: \$450,000

Purpose: The purpose of this amendment is to correct the amount of additional funds needed under 22-PAF07236 from what was reported to the on Regents July 21, 2022 so that Dr. Narla may continue to perform testing on the cellular effects of a series of small molecule activators of PP2A on cancer cell lines.

University Employee; University Title; Relationship with Rappta Therapeutics Oy

- Goutham Narla; Professor, Internal Medicine – Genetic Medicine; Partial Owner

Project #4

**Fourth Amendment to Other Sponsored Activity Agreement between the University and Rappta Therapeutics Oy
Reviewed by the Medical School Conflict of Interest Board**

Project Information

Title: Testing of small molecule PP2A activators in cellular and in vivo systems

U-M Project ID: 23-PAF03319
under AWD016016

Direct Sponsor: Rappta Therapeutics Oy

Principal Investigator/Department: Goutham Narla, Internal Medicine - Genetic Medicine

Agreement Originally Approved by the Regents: May 21, 2020

First Amendment Approved by the Regents: December 9, 2021

Second Amendment Approved by the Regents: July 21, 2022

Current Project Duration: Thirty-One (31) Months
Additional Project Duration: Fifteen (15) Months

Current Funding Support: \$2,300,000
Additional Funding Support: \$850,000

Purpose: The purpose of this amendment is to add additional time and funds so that Dr. Narla may continue to perform additional testing on the cellular effects of a series of small molecule activators of PPSA cancer cell lines.

University Employee; University Title; Relationship with Rappta Therapeutics Oy

- Goutham Narla; Professor, Internal Medicine – Genetic Medicine; Partial Owner

Project #5

Second Amendment to Other Sponsored Activity Agreement between the University and Rappta Therapeutics Oy Reviewed by the Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Characterizing role of novel PP2A activators in human cancer	U-M Project ID: 23-PAF03320
Direct Sponsor: Rappta Therapeutics Oy	
Principal Investigator/Department: Goutham Narla, Internal Medicine - Genetic Medicine	
Agreement Originally Approved by the Regents: October 21, 2021 First Amendment Approved by the Regents: July 21, 2022	
Current Project Duration: Seventeen (17) Months Additional Project Duration: Seventeen (17) Months	Current Funding Support: \$1,400,000 Additional Funding Support: \$1,000,000
Purpose: The purpose of this amendment is to add additional time and funds so that Dr. Narla may continue to test the cellular effects of a series of 70 small molecule activators of PP2A on a panel of cancer cell lines.	
<u>University Employee; University Title; Relationship with Rappta Therapeutics Oy</u>	
<ul style="list-style-type: none">● Goutham Narla; Professor, Internal Medicine – Genetic Medicine; Partial Owner	